Blockchain Registration Transaction Record
Lexaria Bioscience Announces Promising Results in Ongoing Animal Study
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) announces promising results from ongoing animal study WEIGHT-A24-1, showing top performers in reducing blood sugar levels. The study's focus on DehydraTECH-liraglutide and DehydraTECH-CBD formulations could lead to more effective solutions for diabetic control.
This news matters to individuals interested in diabetes treatment and drug delivery technology. The promising results could potentially lead to more effective solutions for diabetic control, offering hope to those affected by the condition. Additionally, it reflects the innovation and progress in drug delivery technology, which could have broader implications in the pharmaceutical industry.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0x1ee778ce0e845a5fccf0258376a8f86e68f9b9a62fb402c71c95ccafc0e60c63 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | filo3_Xp-1e4e7c463683e428ce851ed2dd4c19a5 |